Article révisé par les pairs
Titre:
  • HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil
Auteur:Di Leo, Angelo; Gancberg, David; Larsimont, Denis; Tanner, Minna; Järvinen, Tero; Rouas, Ghizlane; Dolci, Stella; Leroy, Jean-Yves; Paesmans, Marianne; Isola, Jorma; Piccart-Gebhart, Martine
Informations sur la publication:Clinical cancer research, 8, 5, page (1107-1116)
Statut de publication:Publié, 2002
Sujet CREF:Cancérologie
Sciences bio-médicales et agricoles
MeSH keywords:Aged
Anthracyclines -- administration & dosage
Antigens, Neoplasm
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Biomarkers, Tumor -- genetics
Breast Neoplasms -- drug therapy -- genetics -- pathology
Clinical Trials, Phase III as Topic
Cyclophosphamide -- administration & dosage
DNA Topoisomerases, Type II -- genetics
DNA-Binding Proteins
Disease-Free Survival
Female
Fluorouracil -- administration & dosage
Gene Amplification
Humans
In Situ Hybridization, Fluorescence
Lymph Nodes -- pathology
Methotrexate -- administration & dosage
Middle Aged
Mutation
Predictive Value of Tests
Randomized Controlled Trials as Topic
Receptor, ErbB-2 -- genetics
Treatment Outcome
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:1078-0432
info:scp/0036091354
info:pmid/12006526
VX-005569

Documents en relation

DI-fusion